THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.

If you are in any doubt about the course of action to take: You should immediately consult your stockbroker, bank manager, solicitor, accountant or other independent financial adviser (being, in the case of Irish resident shareholders, an adviser authorised or exempt under the Investment Intermediaries Act 1995 of Ireland or an authorised investment firm within the meaning of the European Communities (Markets in Financial Instruments) Regulations 2017 and in the case of UK resident shareholders, an independent financial adviser who is authorised to carry on a regulated activity under the Financial Services and Markets Act 2000 of the UK).

If you have sold or transferred all your shares in Roebuck Food Group plc: Please pass this document and the accompanying Form of Proxy to the purchaser or transferee or to the stockbroker, bank or the agent through whom the sale or transfer was effected, for transmission to the purchaser or transferee. If you have sold or otherwise transferred some of your Shares, you should immediately consult the stockbroker, bank, or other agent through whom the sale or transfer was effected.

THIS DOCUMENT IS NOT A PROSPECTUS.

This document has not been examined or approved and will not be examined or approved by any regulatory authority or securities market or stock exchange.

No public offer of securities is made by or in connection with this document.

The Company's Ordinary Shares are admitted to trading on AIM: AIM is a market operated by the London Stock Exchange, designed primarily for emerging or smaller companies to which a higher investment risk tends to be attached than to larger or more established companies. AIM securities are not admitted to the Official List of the United Kingdom Listing Authority. A prospective investor should be aware of the risks of investing in such companies and should make the decision to invest only after careful consideration and, if appropriate, consultation with an independent financial adviser. The London Stock Exchange has not itself examined or approved the contents of this document. Prospective investors should read this document in its entirety.

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. It is expected that admission to AIM will become effective and dealings in the New Ordinary Shares will commence at 8.00 a.m. **1 December 2026.**

ROEBUCK FOOD GROUP plc

(Registered in Ireland under the Companies Act 2014 of Ireland, No 51842)

Placing of 62,291,018 new Ordinary Shares at 9p each

Subscription for 21,022,999 new Ordinary Shares at 9p each

Extraordinary General Meeting

J&E Davy Unlimited Company ("Davy"), which is regulated in Ireland by the Central Bank of Ireland, are acting exclusively for Roebuck and no-one else in connection with the Placing. Davy will not regard any other person (whether or not a recipient of this document) as its customer or be responsible to any other person for providing the protections to customers of Davy nor for providing advice in relation to the transactions and arrangements described in this document. Davy is not making any representation or warranty, express or implied, as to the contents of this document. Davy has not approved the contents of, or any part of, this document and no liability whatsoever is accepted by Davy for the accuracy of any information or opinions contained in this document or for the omission of any information from this document.

A letter from the Chairman of Roebuck Food Group plc ("the Company") is set out on pages 8 to 27 of this Circular. Notice convening an Extraordinary General Meeting of the Company to be held at South Bank House, Barrow Street, Dublin D04 TR29, Ireland at 9 a.m. on Monday 30 November 2026 is set out on pages 40 to 44 of this Circular. Accompanying this document is a Form of Proxy for use at the Extraordinary General Meeting. To be valid, a Form of Proxy must be completed and returned so as to be received by the Company's Registrar, Computershare Investor Services (Ireland) Limited, at 3100 Lake Drive, Citywest Business Campus, Dublin 24, D24 AK82, Ireland by 9 a.m. on Saturday 28 November 2026.

Status of this Circular

This document:

- is not and should not be construed as a prospectus, whether under the UK POATRs or the Irish IMC Rules or otherwise;
- does not constitute, and the Company is not making, an offer to the public within the meaning of regulation 7 of the UK POATRs or of article 2(d) of the EU Prospectus Regulation 2017/1129 or otherwise;
- is exempt from the general restriction set out in Section 21 of FSMA on the communication of invitations or inducements to engage in investment activity and has not been approved by a person who is authorised under FSMA;
- has not been prepared in accordance with Prospectus Regulation (EU) 2017/1129 or any measures made under that Regulation or the laws of Ireland or of any EU Member State or EEA Treaty adherent State that implement that Regulation or transpose or implement those measures, or in accordance with any equivalent or comparable UK measures;
- has not been reviewed, prior to its being issued, by any regulatory authority in Ireland, in any other EU Member State or EEA Treaty adherent State, or in the United Kingdom, and therefore may not contain all the information required where a document is prepared pursuant to that Regulation or those measures or laws;
- in particular, has not been examined or approved by the UK Financial Conduct Authority or the London Stock Exchange or by Euronext Dublin (The Irish Stock Exchange plc) in their respective capacities as listing authorities or market operators; and
- does not constitute a recommendation regarding securities of the Company;

Without prejudice to this document not being a prospectus, offering document, or a document to which section 1361 of the Companies Act 2014 applies, the Company gives notice that:

- investments may fall as well as rise in value;
- simulated performance may not be a reliable guide to future performance;
- changes in exchange rates may have an adverse effect on the value, price, or income of the New Ordinary Shares; and
- although the Ordinary Shares are quoted on AIM, it may be difficult for investors to sell or realise the securities and/or obtain reliable information about their value or the extent of the risks to which they are exposed.

Attendance and voting at the EGM

- A form of proxy for use at the EGM is enclosed ("**Form of Proxy**"). If you wish to validly appoint a proxy to attend the EGM on your behalf, the Form of Proxy should be completed and signed in accordance with the instructions printed thereon, and returned by post or by hand to the Company's Registrar, Computershare Investor Services (Ireland) Limited, 3100 Lake Drive, Citywest Business Campus, Dublin 24, D24 AK82, Ireland as soon as possible, but in any event so as to be received by the Company's Registrar no later than 9:00 a.m. on Saturday 28 November 2026 . Further instructions on how to appoint a proxy are set out in the notes to the Notice of EGM and on the Form of Proxy.
- The completion and return of a Form of Proxy will not legally preclude you from attending and voting in person at the EGM, or any adjournment thereof, should you wish to do so. We strongly encourage Shareholders unable to attend to submit their Forms of Proxy or appoint their proxy electronically in order to ensure they can vote and be represented at the EGM without the need to attend in person.

Cautionary note regarding forward-looking statements

- This document includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "plans", "projects", "anticipates", "expects", "intends", "may", "will", or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include matters that are not historical facts. They appear in a number of places throughout this document and include statements regarding the Directors' current intentions, beliefs or expectations concerning, among other things, the Existing Group's results of operations, financial

condition, liquidity, prospects, growth, strategies and the Existing Group's markets. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Actual results and developments could differ materially from those expressed or implied by the forward-looking statements.

- Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements in this document are based on certain factors and assumptions, including the Directors' current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Group's operations, results of operations, growth strategy and liquidity. Whilst the Directors consider these assumptions to be reasonable based upon information currently available, they may prove to be incorrect. Save as required by law or by the AIM Rules, the Company undertakes no obligation to publicly release the results of any revisions to any forward-looking statements in this document that may occur due to any change in the Directors' expectations or to reflect events or circumstances after the date of this document.

Notice to overseas persons

- The distribution of this document into jurisdictions other than the United Kingdom and Ireland may be restricted by law. Any failure to comply with any of the restrictions may constitute a violation of the securities law of any such jurisdiction.
- In particular such documents should not be distributed, forwarded to or transmitted to the United States or any Restricted Jurisdiction. No Shares of the Company have been, and none will be, registered under the United States Securities Act 1933, as amended, or under the securities laws of any state, district or other jurisdiction of the United States, or under the securities laws of any other Restricted Jurisdiction or any state, province or territory thereof or any other jurisdiction outside the United Kingdom or Ireland.
- The New Ordinary Shares have not been approved or disapproved by the US Securities and Exchange Commission, or any other securities commission or regulatory authority of the United States or of any other jurisdiction, nor have any of the foregoing authorities passed upon or endorsed the merits of the Company or the New Ordinary Shares nor have they approved this document or confirmed the accuracy or adequacy of the information contained in this document.

Notice to potential investors generally

- In deciding whether or not to invest in the Ordinary Shares, prospective investors should rely only on the information contained in this document. No person has been authorised to give any information or make any representations other than as contained in this document and, if given or made, such information or representations can not and must not be relied on as having been authorised by the Company, the Directors, or Davy.
- The delivery of this document shall not, under any circumstances, create any implication that there has been no change in the affairs of the Company since the date of this document or that the information contained herein is correct as at any time after its date.
- Investment in the Company carries risk. There can be no assurance that the Company's strategy will be achieved and investment results may vary substantially over time. Investment in the Company is not intended to be a complete investment programme for any investor. The price of Ordinary Shares and any income from Ordinary Shares can go down as well as up and investors may not realise the value of their initial investment. Potential investors should carefully consider whether an investment in Ordinary Shares is suitable for them in light of their circumstances and financial resources and should be able and willing to withstand the loss of their entire investment (see Part III "Risk Factors" of this document).
- Potential investors contemplating an investment in Ordinary Shares should recognise that their market value can fluctuate and may not always reflect their underlying value. Returns achieved are reliant upon the performance of the Group. No assurance is given, express or implied, that Shareholders will receive back the amount of their investment in Ordinary Shares.
- Investment in the Company is suitable only for financially sophisticated individuals and institutional investors who have taken appropriate professional advice, who understand and are capable of assuming the risks of an investment in the Company and who have sufficient resources to bear any losses which may result therefrom.
- Potential investors should not treat the contents of this document or any subsequent communications from the Company, the Directors, or Davy as advice relating to legal, taxation, investment or any other matters. Potential investors should inform themselves as to:

- the legal requirements within their own countries for the purchase, holding, transfer, or other disposal of Ordinary Shares;
- any foreign exchange restrictions applicable to the purchase, holding, transfer or other disposal of Ordinary Shares that they might encounter; and
- the income and other tax consequences that may apply in their own countries as a result of the purchase, holding, transfer or other disposal of Ordinary Shares.

Potential investors must rely upon their own representatives, including their own legal advisers and accountants, as to legal, tax, investment or any other related matters concerning the Company and an investment therein.

Market, industry and economic data

- Unless the source is otherwise identified, the market, industry, and economic and industry data and statistics in this document constitute the Directors' estimates, using underlying data from third parties. The Company has obtained market and economic data and certain industry statistics from internal reports, as well as from third party sources as described in the footnotes to such information. The Company confirms that all third-party information set out in this document has been accurately reproduced and that, so far as the Company is aware and has been able to ascertain from information published by the relevant third party, no facts have been omitted which would render the reproduced information inaccurate or misleading. Where third party information has been used in this document, the source of such information has been identified.
- Such third-party information has not been audited or independently verified.
- This document includes market share, industry data and forecasts that the Company has obtained from industry publications, surveys and internal company sources.
- Statistics are subjective and judgmental.
- Market and industry data are inherently predictive and speculative and is not necessarily reflective of actual market conditions. Statistics in such data are based on market research, which itself is based on sampling and subjective judgments by both the researchers and the respondents, including judgments about what types of products and transactions should be included in the relevant market.
- The value of comparisons of statistics for different markets is limited by many factors, including:
  - the markets are defined differently;
  - the underlying information was gathered by different methods; and
  - different assumptions were applied in compiling the data.
- Consequently, the industry publications and other reports referred to above generally state that the information contained therein has been obtained from sources believed to be reliable, but that the accuracy and completeness of such information is not guaranteed and, in some instances, these reports and publications state expressly that they do not assume liability for such information. Specifically, Davy have not authorised the contents of, or any part of, this document and accordingly no liability whatsoever is accepted by Davy for the accuracy or completeness of any market or industry data which is included in this document.

No incorporation of websites

- The contents of the Company's website (nor any other website whether or not accessible via hyperlinks from the Company's website) do not form part of this document and potential investors should not rely on them.

Rounding

- The financial information contained in this document, including that financial information presented in a number of tables in this document, has been subject to rounding adjustments. Therefore, the actual arithmetic total of the numbers in a column or row in a certain table may not conform exactly to the total figure given for that column or row. In addition, certain percentages presented in the tables in this document reflect calculations based upon the underlying information prior to rounding, and, accordingly, may not conform exactly to the percentages that would be derived if the relevant calculations were based upon the rounded numbers.

Governing law and interpretation

- This document is regulated by Irish law and any matters arising under it are subject to the exclusive jurisdiction of the Irish courts.
- Certain terms used in this document are defined and certain technical and other terms used in this document are explained in Part VIII of this document under the heading "Definitions".
- All times referred to in this document and the Form of Proxy are, unless otherwise stated, references to Dublin, Ireland time.

TABLE OF CONTENTS

		Page
Cover page		**1**
Notices and Cautionary Statements		**2**
Directors, Secretary, Registered Office, and Advisers		**6**
Admission Statistics, **Expected Timetable of Principal Events**		**7**
Part I	**Letter from the Chairman of Roebuck Food Group plc**	**8**
Part II	**Additional Information**	**28**
Part III	**Risk Factors**	**31**
Part IV	**Financial Information**	**35**
Part V	**Definitions**	**37**
Part VI	**Notice of Extraordinary General Meeting**	**40**

DIRECTORS, SECRETARY, REGISTERED OFFICE AND ADVISERS

Directors	Tommy Conway (Non-executive Chairman) Justin McCarthy (Chief Executive) Aidan Hughes (Finance Director) Seán Savage (Non-Executive Director)
Company Secretary	Aidan Hughes
Registered Office	6th Floor South Bank House Barrow Street Dublin 4 D04 TR29 Ireland
Bookrunner, Nominated Adviser & Broker	Davy Davy House 49 Dawson Street Dublin 2 D02 PY05 Ireland
Auditors	Grant Thornton Chartered Accountants 13-18 City Quay Dublin 2 D02 ED70 Ireland
Legal advisers to the Company	Mason Hayes & Curran LLP South Bank House Barrow Street Dublin 4 D04 TR29 Ireland
Legal Advisers to the Bookrunner	William Fry LLP 2 Grand Canal Square Dublin 2 D02 A342 Ireland
Registrars	Computershare Investor Services (Ireland) Limited 3100 Lake Drive Citywest Business Campus Dublin 24 D24 AK82 Ireland
Company website	www.roebuckfoodgroup.com

ISSUE STATISTICS

Number of Existing Shares in issue at the date of this document	101,143,944
Number of Existing Shares expected to be in issue immediately prior to the record time	101,143,944
Nominal value per Existing Share	€0.025
Number of Placing Shares to be issued at the Issue Price	62,291,018
Number of Subscription Shares to be issued at the Issue Price	21,022,999
Issue Price	9p
Total number of New Ordinary Shares in issue immediately following Admission	83,314,017
Gross proceeds of the Placing	Approximately €6,729,314
Gross proceeds of the Subscription	Approximately €2,271,120
ISIN for the Shares	IE0006447985

EXPECTED TIMETABLE OF PRINCIPAL EVENTS [NOTE]

Announcement of the proposed Placing and Subscription,	30 October 2026
Publication and posting of this document	6 November 2026
Record time and date for voting at the Extraordinary General Meeting	6:00 p.m. on 26 November 2026
Latest time and date for receipt of Proxy Forms for the Extraordinary General Meeting	9:00 a.m. on 28 November 2026
Extraordinary General Meeting	9:00 a.m. on 30 November 2026
Admission and commencement of dealings in new Ordinary Shares	8:00 a.m. on 1 December 2026
Euroclear Shareholders' accounts credited in respect of New Ordinary Shares	As soon as possible after 8.00 a.m. on 1 December 2026

NOTE References to times in this Circular are to Dublin, Ireland time.

The dates and timing of the events in the timetable and in the rest of this Circular are indicative only and may be subject to change.

If any of the times or dates should change, the revised times and/or dates will be notified by an announcement through an RNS.

PART I

LETTER FROM THE CHAIRMAN OF ROEBUCK FOOD GROUP plc

Roebuck Food Group plc

(registered in Ireland No 51842)

Directors	*Registered Office*
Tommy Conway (Non-executive Chairman)	6th Floor
Justin McCarthy (Chief Executive)	South Bank House
Aidan Hughes (Finance Director)	Barrow Street
Seán Savage (Non-Executive Director)	Dublin 4
	D04 TR29
Secretary: Aidan Hughes	Ireland
	6 November 2026

Placing of 62,291,018 new Ordinary Shares at 9p each

Subscription for 21,022,999 new Ordinary Shares at 9p each

Extraordinary General Meeting

1. INTRODUCTION

Proposed Fundraising

On 30 October 2026 Roebuck issued an announcement stating that it had agreed, subject to shareholder approval of resolutions at the EGM to raise up to €10 million to fund the Group by means of:

- a placing of new Ordinary Shares to certain institutional, professional, and other investors at a price of 9 pence per Ordinary Share ("**the Placing Price**") (the "**Placing**"); and

- subscriptions for new Ordinary Shares from other investors at the Placing Price (the "**Subscription**"); and

the foregoing Placing and Subscription being together referred to as the "**Fundraising**".

In conjunction with this announcement, the Company announced that it had decided to utilise a capital access window facility ("**Capital Access Window**") to provide it with a voluntary mechanism to implement a temporary pause in the trading of its shares on AIM to facilitate reaching a broader range of investors, and to provide pricing stability during the Fundraising. Accordingly, trading in the Ordinary Shares of the Company was suspended with effect from 7.30 a.m. on 2 November 2026.

On 5 November 2026 Roebuck issued an announcement stating that:

- an aggregate of 62,291,018 new ordinary shares of €0.025 each ("**Ordinary Shares**") in the capital of the Company (the "**Placing Shares**") had been successfully placed by Davy at the Placing Price to raise gross proceeds of approximately €6,729,314; and

- the Company had received direct agreements to subscribe for 21,022,999 Ordinary Shares ("**the Subscription**") at the Placing Price from certain investors unable to participate in the Placing to raise gross proceeds of approximately €2,271,120.

such that the Fundraising from the Placing and the Subscription is expected to raise gross proceeds of €9,000,434, resulting in a 45.17% dilution of existing shareholders.

In conjunction with this second announcement, the Company announced the closure of the Capital Access Window, and trading in the Company's shares resumed at 8:00 am on 6 November 2026.

Use of Proceeds of Fundraising

The proceeds of the Fundraising, net of transaction costs, are intended to be deployed to support the next phase of growth in GlasPort Bio and GlasPort Rumen Tech, summarised under the following headings:

- Working capital: Supporting the operational funding and cash flow requirements of a rapidly scaling commercial business across multiple geographies;

- Commercial deployment: . Capital to scale commercial rollout across existing and new customers, funding farm installations, Compli360 infrastructure and processor-led programmes across dairy, beef, pig, and duck sectors to accelerate growth in slurry treated with GasAbate.

- Co-Benefits R&D: R&D strategy to expand GlasPort's value proposition beyond methane abatement, advancing ammonia reduction, dosage optimisation, and validation of wider economic and environmental co-benefits, including improved animal performance, soil health, water quality, chemical fertiliser reduction, and odour reduction.

- Compli360 Optimisation: Develop Compli360 system to by investing in next-generation IoT infrastructure, focusing on reducing unit costs at scale, accelerating installation timelines, and reducing overall complexity — making deployment faster, cheaper, and more scalable across all farm types over the course of the year.

- Team Expansion: Grow the commercial, technical, and operations team to support geographic expansion across Europe. Grow internal capability across regulatory affairs, engineering, and data management to support market and technology development.

- International Partnerships: Establishing commercial partnerships with food processors, co-ops, and distribution partners in new markets. The key markets being targeted will be dairy markets in key EU member states.

- Rumen Tech: Funds used to advance the development of anti-methanogenic ruminant products.

- Ownership Simplification: A small minority of the proceeds may be used to support the simplification of the ownership structures of GlasPort and Rumen Tech, through the acquisition of shares from certain minority shareholders, should suitable opportunities arise.

Loan to GlasPort Companies

Portion of the proceeds of the Fundraising will, immediately following completion of the Fundraising, be applied by Roebuck in providing GlasPort Bio with an unsecured loan of €1 million ("**the Loan**") for its requirements prior to completion of the Potential Acquisition (described below in section 2 of this letter), the funds from which Loan may be advanced by GlasPort Bio to GlasPort Rumen Tech with Company consent. The Loan will have an interest rate of 2% per annum above ECB base rate, payable annually in arrears. The Loan will have a one year term, thereafter subject to repayment on one year's notice, subject to accelerated repayment in the case of an insolvency event in the Company, GlasPort or Rumen Tech.

The remainder of the Fundraising will be deployed post completion of the Potential Acquisitions. If the Potential Acquisition for any reason does not complete, Roebuck will explore other methods of investing the proceeds into GlasPort Bio and GlasPort Rumen Tech. Failing this, the remaining funds will be returned to shareholders.

The entry into the Loan constitutes a related party transaction for the purposes of Rule 13 of the AIM Rules. The Directors of the Company consider, having consulted with the Company's Nominated Adviser, Davy, that the terms of the Loan are fair and reasonable insofar as the shareholders of the Company are concerned.

It is the Board's intention that the net proceeds of the Fundraising will be applied to support the development and growth of GlasPort Bio and GlasPort Rumen Tech, and will not be used to fund or discharge any legacy costs or liabilities associated with existing non-core activities of Roebuck.

Shareholder Vote

The Placing and the Subscription are subject to shareholder approval by the passing of a resolution at the EGM convened for 30 November 2026, Notice of which is set forth in Part VI of this document.

2. BACKGROUND TO AND REASONS FOR THE FUNDRAISING

Call Option

In February 2025 Roebuck acquired a call option over the shares of a majority of the shareholders ("**Original Shareholders**") in GlasPort Bio entitling the Group to increase its shareholding in GlasPort Bio from 37.3% to 82.3% (such percentages being calculated pre-management growth-share dilution) (the "**Call Option**"). This Call Option became exercisable from 7 August 2026. The price of the shares subject to the Call Option was set at the post-money value per share of the original transaction (€16.08 million), plus three additional increments based on pre- agreed developmental milestones (€ 30.08 million).

The Original Shareholders and Roebuck can, by mutual agreement, elect to settle consideration for exercise of the Call Option entirely in Roebuck shares. Settlement of all three developmental milestones during the Call Option window would increase the total cost to exercise the Call Option to approximately £13.2 million. Roebuck has initiated discussions with the Original Shareholders regarding exercise of the Call Option, with a view to consideration being settled entirely in new Roebuck ordinary shares. Whilst discussions have reached an advanced stage, there is no certainty that the option will be exercised at this time.

Potential Acquisition

In conjunction with these discussions, Roebuck is in discussions with the other shareholders of GlasPort Bio not subject to the Call Option, and with the other shareholders of GlasPort Rumen Tech, with a view in each case to acquire full ownership of 100% of the shares, (excluding management growth-shares).

If Roebuck and the shareholders of GlasPort Bio and GlasPort Rumen Tech agree to proceed with these transactions ("**the Potential Acquisition**"), depending on their terms and conditions, a separate Circular detailing them may be issued by Roebuck and a separate EGM convened.

Whilst discussions regarding the Potential Acquisition are at an advanced stage, there is no certainty that either element will be completed, and if so, to what extent. While exact terms have yet to be determined, the consideration for any Potential Acquisition will result in the issuance of a significant amount of new Roebuck shares which will be dilutive to existing shareholders.

It is anticipated that the current Roebuck Long-Term Incentive Plan, adopted by shareholders in 2023, will be used for GlasPort Bio and GlasPort Rumen Tech employees, as part of the Potential Acquisition.

3. ABOUT ROEBUCK FOOD GROUP plc

Roebuck Food Group plc

Roebuck was founded in 1975 as Norish Food City Ltd and became a public company with the name Norish plc in 1986. Until 2021, the Group operated strategically located temperature-controlled storage centres, which provided storage, freezing, picking, and order assembly services to food companies engaged in processing, wholesaling and retailing. Those cold stores were disposed of in 2021.

Roebuck now focuses on growth and innovation within the food and agribusiness sectors. The Group's strategic vision includes the advancement and implementation of climate mitigation technologies throughout the agricultural supply chain. It currently operates in two divisions:

- the Plant-Based Ingredient Division, currently consisting of Moorhead & McGavin Limited, which is involved in plant based food and food ingredient distribution, and Foro Food Solutions Limited, a food sourcing and distribution specialist; and


- the Livestock Sustainability and Biotechnology division, consisting of its 37.31% interest in GlasPort Bio, with its patented GasAbate system that reduces emissions from animal-manure storage and 16%

interest in GlasPort Rumen Tech which is developing a feed additive that improves feed efficiency while reducing methane emissions from livestock.

Roebuck's recent history features these highlights:

- 2021 – Sale of cold storage division to Japanese Nichirei Corporation for a gross consideration of £56.1 million.
- 2021 – Return of c.£50 million to shareholders via. capital return of £1.66 per ordinary share.
- 2023 – Raising of £2.5 million in November 2023 to support the acquisition of Moorhead & McGavin.
- 2024 - Exited the dairy business with the disposal of Cantwellscourt Farm Ltd in May 2024, and the animal protein trading division Townview Foods Ltd in September 2024, leaving Moorhead & McGavin Ltd and Foro Food Solutions Ltd as the Group's remaining operating businesses.
- January 2025 - Completed equity fundraising, by placing and subscription, of approx. £8.2 million
- February 2025 – Completed the acquisition of 37.3% of GlasPort Bio (together with Call Option to increase shareholding to 82.3%) and 16% in GlasPort Rumen Tech.

The following chart illustrates the Company's share price and selected corporate developments since 2021:



Note 1: Market Capitalization as at 27 October 2026;

Note 2: Interim Results June 2026;

Note 3: Financial year ended 31 December 2025;

Note 4: Factset as at 27 October 2026

4. BOARD AND GOVERNANCE

Tommy Conway, Non-Executive Chairman (65)

Tommy Conway has over 30 years of investment banking experience with J&E Davy, NCB Group and Investec Corporate Finance, and is currently Managing Director of TCCA Ltd. He has an extensive track-record in agrifood mergers and acquisitions, including the sale of the then Norish plc cold stores division in 2021. He was appointed to the Board in 2025, having advised on the Group's investments in GlasPort Bio and GlasPort Rumen Tech. He holds a Bachelor's degree in Agricultural Science and a Master's degree in Climate Change and Financial Services.

Sean Savage, Non-executive Director (80)

Sean Savage was appointed to the Board in 2012, having previously held senior management positions with Manor Farm Poultry and Cadbury (Ireland) Ltd. He was the co-founder and joint owner of Eatwell (UK) Ltd, which was successfully disposed of in 2003.

Aidan Hughes, Finance Director and Secretary (61)

Aidan Hughes joined Roebuck in 1996, and became Finance Director in 2006. Along with former CEO Kieran Mahon, he led significant repositioning of the then Norish plc cold stores division prior to its successful sale in 2021 and £50m capital return to shareholders. Mr Hughes is a Chartered Accountant with extensive experience in corporate finance in the agri-food supply chain and chilled storage sectors

Justin McCarthy Chief Executive Officer (49)

Justin McCarthy was appointed to the Board on 31 October 2026 while retaining his existing responsibilities at GlasPort Bio and GlasPort Rumen Tech. He has broad experience in the agricultural sector, having worked with ABP Food Group, Dawn Meats, and Teagasc. He was previously CEO and Editor of the Irish Farmers Journal Group from 2013 to 2022 and brings a combination of leadership, commercial insight, and knowledge of agriculture and global food sector. Mr McCarthy complemented his executive career with postgraduate and executive education at Harvard Business School and UCD Michael Smurfit Graduate Business School, combining international business education with significant practical leadership experience.

Padraic Lenehan Finance Director Designate (52)

Padraic Lenehan is an experienced finance executive with over two decades of leadership in the agri-food sector. He is a former Financial Director and Company Secretary of Donegal Investment Group plc, where he oversaw finance, governance and compliance. He brings extensive board-level, operational and strategic expertise to Roebuck and the GlasPort companies.

Padraig McManus, Non-executive Chairman-designate (75)

Mr McManus is a former Chief Executive of ESB, Chairman of Eir and Chairman of the Greenlink Interconnector Project. He has extensive senior leadership and board experience. He was Chairman and President of the Council of the Economic and Social Research Institute and has held several senior board and advisory positions across a range of Irish operations

Management and Governance Changes

Padraic Lenehan, recently appointed as Chief Financial Officer of GlasPort, will become Chief Financial Officer of Roebuck and join its Board at completion of the Placing and Subscription. He will replace Aidan Hughes who will step down from the Board and from the role of Finance Director and Secretary at completion of the Placing and Subscription and will depart from the business.

Padraig McManus will join the Board and assume the role of Chair of Roebuck at completion of the Placing and Subscription, replacing Tommy Conway as Chairman.

The incoming directors intend to refresh the non-executive directors of Roebuck over the short to medium term as and when suitable candidates can be identified, and there is an active process under way to achieve this.

5. ROEBUCK RESULTS FOR H1 2026

Roebuck's interim results, published on 30 September 2026 highlighted the following:

- Group revenue increased 7.1% to £5.46 million for the six months ended 30 June 2026, reflecting improved trading across the Plant-based Ingredients division.

- GlasPort Bio generated its first meaningful revenues of £293k, following commercial deployments of GasAbate across Ireland, Northern Ireland and Continental Europe.

- Within the plant-based division, the combination of improved sales and better gross margins more than mitigated modest cost increases to see profits at the EBITDA level improve from (£30k) in H1 2025 to £110k EBITDA in H1 2026 (before one-off restructuring costs of £91k).

- Net asset value of 9.2p per share at 30 June 2026.

- Post-H1, a sale and leaseback of M&M's Motherwell facility was completed, realising £850k net proceeds.

- The Roebuck Board announced a strategic refocusing of the Group's business on GlasPort Bio, with active consideration being given to exercising the GlasPort Bio Call Option and assessment of quantum of capital required to fund growth at GlasPort and Rumen Tech.

- The Board announced a leadership transition, with Kieran Mahon stepping down as an executive director on 30 September 2026, with Justin McCarthy (current CEO of GlasPort Bio) to become Group CEO on 31 October 2026.

- Balance sheet highlights

30 June 2026	£ million
Non-current assets	8.92
Current Assets	3.96
Total Assets	12.88
Cash & Cash Equivalents	1.16
Total Borrowings	1.65
Net Debt	0.49
Current Liabilities	2.97
Group Net Assets	9.29
Equity Attributable to Roebuck Shareholders	6.18

The consolidated balance sheet of the Group as at 30 June 2026 from the Company's interim results published on 30 September 2026 is set forth in Part IV of this document.

In addition, H1 saw GlasPort's commercial rollout accelerating, with management expecting a further 40-45 installations expected in H2 2026 and deployment forecast across approximately 90 farms with c.15,000 dairy cows by year end.

6. GROUP RE-FOCUS

As part of the Group's refocus, Roebuck has been progressing the divestment of the Foro Food Solutions and Moorhead & McGavin (together "**the Legacy Businesses**") to simplify the Group and focus its capital, management, resources and future growth strategy on GlasPort and Rumen Tech. Whilst binding contracts have not yet been signed, the Company is at an advanced stage of the process for the disposal of Foro Food Solutions Limited.

The Legacy Businesses had net debt of £544,000 as at 30 October 2026, which is expected to be repaid in full following their divestment. Other debt-like items include restructuring costs associated with the outgoing executive directors of £285,000, and obligations under the long-term lease of the Motherwell property. It is anticipated that the net proceeds of the disposal of the Legacy Businesses will yield sufficient funds to cover the foregoing costs

Following completion of these disposals and the Proposed Transaction, the Group's strategy will be centred on the development and commercialisation of GlasPort Bio's GasAbate and Compli360 technologies and the continued development of GlasPort Rumen Tech. This represents a deliberate repositioning of Roebuck away from its legacy food distribution and plant-based ingredients activities, with the objective of creating a simpler corporate structure, reducing cost and management complexity, and directing capital towards the businesses which, in the opinion of the Directors, offer the strongest opportunity for long-term growth.

7. THE GLASPORT BUSINESSES

GlasPort Bio, was founded in Galway, Ireland, in 2018, as an agricultural sustainability company dedicated to significantly reducing GHG emissions from agriculture. GlasPort Rumen Tech was spun out of GlasPort Bio in 2024, in light of the two companies' distinct products.

Financial information relating to GlasPort Bio is set forth in Part IV of this document.

GlasPort Investment Highlights to date

GlasPort Bio has proven technology, commercial traction and is developing multiple pathways to long-term value creation.

- Industry Validation
  - Arla Europe's Largest Dairy Co-Op: approved for the Arla FarmAhead incentive programme across 7 European countries
  - Commercialised technology is deployed on c. 90 farms across +15,000 cows and 1,600 sows, expected by management.
  - Strategic relationships are developing with leading EU processors and food manufacturers
- Proven Methane Solution and Regulatory Tailwinds.
  - A market-ready solution addressing a growing regulatory imperative and a vast global opportunity.
  - Aiming for inventory listing inclusion in Ireland and internationally.
- Robust Measure, Record and Verify (MRV) System.
  - Proprietary GasAbate + Compli360 platform to support data for emissions verification, regulatory compliance and Scope 3 reporting.
  - Independent Carbon Trust assurance of emissions performance.
- Improving Financial Profile.
  - Recurring revenue model from additive and MRV from a once off Capex expense.
  - Management estimate of €1.15m revenue for FY27 based on 2026 installations alone.
- Additional Co-benefits for Farmers.
  - Co-benefits identified and under validation, include lower mineral fertiliser requirements, improved. slurry nutrient value, enhanced animal performance, carbon payment opportunities and access to sustainability-linked support schemes, all with the potential to improve farm economics.
- Patent Protection
  - Extensive patents granted and new patent filings.

In addition, GlasPort Rumen Tech has a development stage Product - RumenGlas. The pathway to commercialization for this product is planned to be through an EFSA regulatory approval and with a strategic global feed partner, supported by a scalable feed additive and expanding patent protection across key markets.

GlasPort Management Team

The GlasPort Companies have an experienced management team supported by leading scientific expertise and strong industry relationships.

Prof Vincent O'Flaherty. CSO & Co-Founder is a world-leading expert in microbial ecology with over 160 peer-reviewed research articles. Lead inventor of GlasPort Bio's anti-methanogenic technology. GlasPort Bio is the third company founded from this pioneering research.

Dr Ruairí Friel CRO & Co-Founder. PhD in Microbiology, University of Glasgow. Expertise in product development and intellectual property management. Proven track record of successfully bringing products to market. Previous success in out-licensing within the agricultural sector.

Justin McCarthy Chief Executive Officer. Broad experience in the agricultural sector, having worked with ABP Food Group, Dawn Meats, and Teagasc. He was previously CEO of the Irish Farmers Journal Group from 2013 to 2022 and brings a combination of leadership, commercial insight, and knowledge of agriculture and global food sector

Padraic Lenehan Chief Financial Officer. Experienced finance executive with over two decades of leadership in the agri-food sector. Former Financial Director and Company Secretary of Donegal Investment Group plc, where he oversaw finance, governance and compliance. Brings extensive board-level, operational and strategic expertise to GlasPort Bio.

The Senior Management Team consists of Joe Lenehan, Chief Technology Officer; Dr Camilla Thorn, Scientific Lead; Hem Mulders, EU Director of Strategic Partnerships; Dr Dermot Hughes, Chief Engineer; Caitríona Morrissey, Chief Delivery Officer; Stephen Fagan, Business Development Manager.

Europe's Emissions Challenge

Meeting emissions targets will require credible, commercially deployable solutions at scale, particularly in agriculture.

Europe


Over 70% of emissions from European agriculture arise from methane and nitrous oxide, as opposed to carbon dioxide. The EU has implemented legally binding 2030 emissions targets for EU member states in the form of the Effort Sharing Regulation (ESR). All but 6 member states are on track to miss their allocated ESR targets. EU countries are faced with a strong policy incentive to accelerate emissions reductions between now and 2030 to minimise ESR fines. The agriculture sector faces a unique emissions challenge for EU, but recognition of livestock methane abatement within the EU Carbon Farming Removal Framework (CRCF) may allow new ways for member states to incentivise emissions reduction.

Within the EU, manure management accounts for 17% of total greenhouse gas (GHG) emissions from agriculture. When manure is stored during the housing period, methane (CH_4) and ammonia (NH_3) are released. As intensive dairy and pig production in many parts of Europe is based on year-round indoor production, this requires large volumes of animal slurry to be stored for long periods with consequent emissions of GHG, noxious and malodorous gases.

Ireland

Ireland may face up to €26.6bn EU compliance costs if ESR targets are not met. Withing these overall national targets, the Irish agricultural sector remains materially off-track to meet 2030 emissions targets, with a -25% reduction required vs current trajectory of just -4.7%.

EU Greenhouse Gas Emissions CO2eq 2024 by NACE (Source: Eurostat)



Livestock Manure Market

Livestock manure-management is a large and underserved market increasingly driven by sustainability. and compliance requirements. The EU and US livestock manure management systems represent a Total Addressable Market (TAM) of €3.2bn, where a 10% market penetration represents a €320m market opportunity for GlasPort.

Increasing regulatory requirements and food processor Scope 3 targets are placing direct pressure on farmers to demonstrate credible emissions reductions. Farmers need practical solutions; these must be low-disruption, retrofittable to existing infrastructure, and economically viable without requiring changes to farming practices. Food processors and retailers need credible Scope 3 reductions; they require verifiable, audit-ready data from their supply chains (rather than estimates or voluntary commitments) to unlock the pathway to insetting credits.

GasAbate and Compli360 – Overview

GlasPort's GasAbate + Compli360 is an integrated manure-management system for methane reduction from stored livestock slurry (liquid manure) and incorporates automated dosing and emissions verification. The solution works by transiently altering the environment within the slurry tank to inhibit methanogens (methane producing microbes), thereby reducing by up to 78% the release of methane, a potent Greenhouse Gas with Global Warming Potential (GWP) 27x and 81x that of carbon dioxide over 100-year and 20-year time horizons, respectively.

The system is suitable for indoor and outdoor slurry storage tanks, such as those found in intensive livestock, pig, and duck production facilities. GlasPort delivers an end-to-end verified emissions solution, ensuring consistent delivery and compliance-ready records. The injection system is fully automated, facilitating remotely monitored dosing. The automated dosing system applies treatment with minimal farmer intervention, avoiding changes to day-to-day farm operations. The built-in Measure, Record and Verify (MRV) system captures all key data required for verification of emissions reduction, required to meet the global reporting standards.

GasAbate + Compli360 benefits from the following key differentiators

- Defensible IP position: Proprietary formulation and delivery system protected by a substantial patent portfolio, with 25 granted patents across all key markets and 5 pending applications across additional markets. GlasPort's integrated hardware requirement and MRV ecosystem creates a strong competitive moat to limit customer circumvention

- Competitive moat: National Inventory Listing (NIL, e.g. the NIL in Ireland) would represent the single largest adoption catalyst, enabling formal recognition and monetisation of emissions reductions. GlasPort's proprietary MRV platform generates the validated, auditable data required to evidence usage and support monetisation at the point of NIL inclusion in a specific national market. NIL inclusion will require both the publication of supporting scientific research and the establishment of a country-specific framework to approve, verify and regulate the methodology.

- Scalable & retrofit-ready deployment: Low-intervention solution with on-farm benefits, designed for deployment across existing cattle and pig farming systems through a retrofit-ready injection system.

Simple integration into existing farm slurry storage infrastructure, and supported by established supply chains.

- Demonstrated emission reductions: reducing methane by up to 78%, hydrogen sulphide emission by 80%, and ammonia by up to 50%. In addition, the technology supports on-farm welfare, improved air quality, enhanced nutrient retention, improving anaerobic digestion feedstock and fertiliser value for crop growth.

- No residues in soil or food chain: GasAbate's active ingredient breaks down fully into oxygen and water, eliminating any potential farmer, food processor or consumer concerns regarding residual build-up in agricultural land used for food production.

Compli360 – MRV system verifies GasAbate usage and impact

The system turns on-farm activity into trusted, verifiable data at scale. The system has four key pillars, as follows:

- Additive measurement and automated dosing: sensors in the slurry tank continuously monitor the volume of manure present and GasAbate is dosed automatically when required.

- Data collection and live reporting: all data flows to the cloud platform daily to dashboards tracking system functionality and slurry treatment

- Verified impact: verified data supports customer demands from processors and food manufacturers, providing the information required for insetting credits

- Informed sales data from additive measurement: GasAbate usage data allows the company to plan for procurement, logistics and new deliveries

Verified Impact

GasAbate has been validated through scientific research, third-party assurance and real-world commercial application.

- 10+ years of R&D – More than a decade of scientific development underpins GasAbate, with deep roots in agricultural and environmental chemistry.

  GasAbate – 20 trial programmes completed or underway, across laboratory, pilot and farm-scale settings

  RumenGlas – 14 in-vitro and in-vivo trials across multiple livestock settings

- Peer-reviewed research – Findings published in peer-reviewed scientific literature, establishing independent academic credibility for the core mechanism.

  GasAbate – 8 published peer reviewed journal articles, 1 article in review and 6 peer reviewed conference papers.

  RumenGlas – 4 published peer reviewed journal articles, 5 peer-reviewed conference papers and 4 peer reviewed journal articles under review.

- Independent field validation – Trials conducted independently by leading research institutions, providing third-party evidence of real-world performance – University of Galway, RISE Research Institutes of Sweden, AFBI Northern Ireland, Danish Technological Institute, Teagasc Ireland, Department of Agriculture, Environment and Rural Affairs Northern Ireland, Queens University Belfast, DLG Germany, and UCD Ireland.

- Carbon Trust Assurance – GasAbate's methane performance is Carbon Trust assured, providing independent credibility for procurement and brand protection teams

- Customer verification – Key customers including Arla have independently verified the technology with research partners.

- Commercial farm deployment – Operating across multiple livestock sectors on commercial farms, demonstrating scalable, on-farm performance beyond controlled trials.

Regulatory and Patent Progress

Patent Protection

- Jurisdictions patents sought in: Europe (EPO), US (USPTO), Canada, Mexico, Brazil, China, Japan, Australia, New Zealand.

- Patent use cases:

  - use and mechanism of action of the GasAbate technology,

  - use of GasAbate-treated material,

  - means of GasAbate delivery,

  - alternative means of gaseous reduction.

- Patent use cases differ across jurisdictions. Total number of patents granted = 25 and 5 patents pending

Hardware and MRV System

- GlasPort's integrated hardware requirement and MRV ecosystem creates a strong competitive moat to limit customer circumvention.

- The Company's proprietary MRV platform generates the validated, auditable data required to evidence usage and support monetisation at the point of Inventory List inclusion.

Inventory Listing

- Inventory listing, e.g. the National Inventory List in Ireland, would represent a significant adoption catalyst, enabling formal recognition and monetisation of emissions reductions.

- For example, in Ireland NIL inclusion will require both the publication of supporting scientific research and the establishment of an EPA-led framework to approve, verify and regulate the methodology.

- In the near term, the value of the MRV platform lies in supporting customer demand, demonstrating emissions reductions and positioning customers ahead of evolving regulatory requirements.

GlasPort Revenue Model

Attractive unit economics supported by recurring revenues and multiple value drivers

GasAbate + Compli360; core recurring revenue

- Primary revenue and margin driver, generating recurring revenue through an ongoing € per litre of solution used.

- Reliable recurring revenue source, providing essential dosing and MRV capabilities required to retain benefits of GasAbate technology.

- Supports an integrated hardware and software offering.

- Highly scalable revenue stream, with limited incremental fixed costs supporting operating leverage as the installed base grows.


Dosing Hardware Installation; revenue enabler

- Hardware deployment underpins growth in recurring revenues, with installations focused on expanding the customer base rather than generating upfront margin.

- Continuous product optimisation & scaling to reduce installation costs, improving margins and opening new market segments.

Recurring Revenue from GasAbate sales (Quarterly, €)

Management forecast the following revenue for 2027.



Multi-layered Monetary Benefit Model for Customers.

Roebuck believes that GasAbate + Compli360 has potential to create value for farmers, processors, retailers, regulators and anaerobic digestion operators. This allows the cost of deployment to be shared amongst stakeholders who benefit, based on several potential value streams as follows:

1. Methane reduction, resulting in sustainability payments

2. Processors and Retailers programmes

3. Enhanced slurry value for anaerobic digestion operators

4. Potential to lower mineral fertilizer usage from improved nutrient retention

5. Potential for improved animal performance in intensive controlled environment production systems

6. Regulatory compliance and emission reduction schemes, potentially reducing the cost of compliance

7. Environmental grant and support programmes

GlasPort – Commercial Traction

Progress to Date


- Significant progress has been made in scaling deployment, building credibility and advancing commercial opportunities.
    - By Q4 2026, management estimate that GasAbate + Compli360 will have been installed on approximately 90 commercial farms across Ireland, the UK and Continental Europe, with management estimates of 15,000 dairy cows and 1,500 sow-places under GasAbate treatment.
    - Management expect 300 kilotons of slurry being treated in 2027 with recurring revenue of €1.15 million expected for 2027
- Over the course of the past 12 months, GlasPort has made a strategic shift from installation count to slurry volume treated as the primary performance metric, reflecting a focus on larger, higher-value farms where commercial opportunity and emissions reduction potential are greatest. GlasPort has also identified potential use-cases beyond dairy, including pig manure, duck farms, and intensive farms where ammonia presents environmental challenges.
- Approved for the Arla FarmAhead Programme: GlasPort has received confirmation that Arla, Europe's largest dairy co-operative, has approved GasAbate system in its FarmAhead incentive programme from 2027 covering the 7 European countries which make up their farmer-owner milk supply base (Belgium, Denmark, Germany, Luxembourg, Netherlands, Sweden, and the UK). This development follows appraisal by Arla, including commercial on-farm pilots, of GasAbate's emissions efficacy together with its complementary MRV Compli360 system. GlasPort will now work with Arla to develop a roll-out strategy to allow their supplier farms access to GasAbate as part of Arla's broader decarbonisation strategy.

This plan illustrates the locations of installations. Each mark represents one or more installations.



Monthly GasAbate Volumes (Litres)

Monthly GasAbate volumes are accelerating rapidly as commercial rollout scales across farm installations.



Note: Figures shown for October, November and December are management estimates.

Benefits to Farmers, Processors, Food Companies and Regulators


GasAbate delivers measurable environmental and economic value across the agricultural supply chain

- Reduced Methane Emission
  - Active ingredient breaks down fully into oxygen and water.
  - Resultant reduced Scope 1 emissions for farmers and Scope 3 emissions for processors and food retailers.
- Regulatory Credibility
  - Meets standards and reporting needs giving regulators a pathway to reduce emissions, and support environmental compliance.
  - Performance is Carbon Trust assured, providing independent credibility.
- Reduced Ammonia Emissions
  - Helps reduce ammonia emissions from stored pig slurry by up to 50%, supporting National Ammonia Reduction Targets.
  - Addresses multiple environmental pollutants through a single intervention
- Auditable Data
  - Compli360 generates measurement, reporting and verification data that meets third-party audit requirements.
  - GlasPort Bio provides verified supply chain emissions data that is increasingly required by regulators, investors, and retail customers

- Farmer Co-Benefits and Savings
  - Simplified slurry management with additional cost savings.
  - Potentially lower mineral fertiliser usage.
  - Improved nutrient retention and enhanced feedstock value for anaerobic digestion
- Improved Farm Safety and Animal Welfare
  - Healthier environment for animals and farm workers alike.
  - Reductions in ammonia and hydrogen sulphide improve air quality in intensive livestock housing

Installation Outlook & Volume Projections

Pathway to rapidly increasing deployments, treated volumes and commercial scale



Slurry treated and GasAbate volume projections are carried forward from the prior year's installation numbers, as per management estimates.

Initial KPI focus	**Clearest Indicator of Commercial Adoption**	**Additional Metric for Commercial Adoption**
The focus has evolved from driving installation growth to increasing additive application and slurry treatment volumes, with the business targeting fewer, larger farms where treatment volumes and economic returns are more attractive.	GasAbate volumes sold clearly demonstrates product and system rollout, showing recurring demand and a clear pathway to long-term growth	Slurry treated demonstrates system throughput and adoption. Additive dosage requirement varies across animal types, meaning slurry volumes treated are not linearly correlated with additive volumes sold.

GlasPort – Research and Development Programme for 2027-2028

GlasPort's planned R&D programme for 2027-2028 is focused on generating robust trial data to support and verify co-benefits. The programme has three main objectives, namely:

- Broaden the value proposition beyond emission reduction to include economic and environmental co-benefits
- Mirror the validation achieved for methane reduction for GasAbate's co-benefits
- Enhance adoption economics with lower net costs and shorter payback period

- In-house and partner trials will be conducted across key areas of commercial importance.
    - Ammonia Reduction: Initial in-house proof-of-concept will aim to establish mechanism and feasibility of improved ammonia emissions reduction. Followed by independent on-farm validation studies to support regulatory acceptance.
    - Animal Performance: In-field pig studies showed improved animal performance. Independent statistically powered studies aim to support claims around feed efficiency, growth rates, nitrogen utilisation, and nitrogen excretion..
    - Agronomy and Soil Health: Initial work has shown improved soil health. Independent studies will aim to validate this across a number of variables including different crops and slurry applications. Studies will aim to show a reduced fertiliser dependency and alignment with regenerative farming practices
    - Water Quality: Run-off and nitrate-loss studies through internal pot trials and external field research will aim to validate improved water quality following GasAbate application.
    - Agitation and Odour: Independent studies aim to build on initial third-party papers around odour reduction. Studies will also aim to develop measurable standards for reduced agitation requirements, delivering enhanced savings to farmers
    - Dosing Optimisation: Dosing optimisation programme will establish the optimal balance between methane reduction achieved and the cost of achieving it or efficacy and affordability.

GlasPort - Commercial deployment and MRV development strategy

GlasPort has set a five-pronged strategy for advancing successful commercial deployment to a scalable, data-driven platform underpinned by emissions verification.

- Reducing upfront hurdle:
    - Partial subsidisation of new installs, recovered by recurring revenue from GasAbate, with ambition to move to breakeven installation pricing.
    - Supporting early adoption of GasAbate in key target markets.
- Socialisation Strategy
    - Building market awareness of GasAbate product and acceptance of its benefits to farmers.
    - Ongoing interactions with customers and regulators.
    - Regular engagement with large-scale processor and co-op sustainability programmes.
- Development of Compli360 v2
    - Improved MRV system giving enhanced data to farmers.
    - Expected to reduce hardware costs, accelerate installation timelines and reduce complexity.
    - Will allow for faster, cheaper and more scalable deployment year-round across all farm types.
- Targeting of Strategic Customers
    - In-depth, regular consultation with key stakeholders across the dairy, beef and swine sectors.
    - Supporting market scaling initiatives with key processor and co-op customers.
- Development of bespoke in-market trials to enhance commercial reputation and accelerate adoption at supply chain level.

- Further Research of GasAbate Benefits

  - Continued production of independent, peer-reviewed research proving the benefits of GasAbate.

  - Proven efficacy of GasAbate would reduce costs per carbon unit abated giving improved unit economics for the customer.

  - Positioning of GasAbate to benefit from developing regulatory pathway in nascent field.

RumenGlas

GlasPort Rumen tech is developing RumenGlas, a differentiated feed additive aimed at delivering enteric methane reduction alongside measurable productivity gains. Initial animal studies have shown meaningful reduction of up to 29% in enteric methane production by ruminant animals.

RumenGlas is a scalable, safe active ingredient that is already extensively used in human food, with an assigned E-number and strong safety profile. The ingredient is easily and widely manufactured, enabling large-scale global rollout without supply chain constraints

RumenGlas offers a potential residue-free approach to reducing enteric methane emissions in ruminant livestock systems. Excess calcium derived from the active ingredient is excreted naturally via faeces, leaving no residues in milk or meat. This eliminates processor, consumer, and taste concerns

Initial trials have shown a measurable performance benefit with potential economic return to the farmer. Improves average daily gain (ADG) by >10% and feed conversion efficiency (FCE) by >15% were recorded in initial trials on beef animals. Dual benefits of improved ADG and FCE, while also reducing methane emissions, have the potential to be a key driver in widescale commercial take-up.

RumenGlas is the result of 10+ years of scientific research, including 14 in-vitro and in-vivo trials across multiple livestock settings. The technology is the subject of 4 published peer-reviewed journal articles, 5 peer-reviewed conference papers and 4 peer-reviewed journal articles under review.

RumenGlas – Route To Market

GlasPort Rumen Tech's strategy is to leverage regulatory approval, patent protection, and strategic partnerships to support global commercialisation of RumenGlas

IP Regulatory and Patents.

RumenGlas requires regulatory approval before commercial sales are permitted on the market.

European Food Safety Authority (EFSA) Zootechnical Feed Additive approval will be sought for both non-lactating feed additive and lactating feed additive through the below process, with Argenta, the Spanish animal feed Regulatory consultancy. . It is intended that Argenta will support the preparation of a regulatory dossier organized under these sections:

1. Identity and Characteristics: Manufacturing process/stability studies/homogenous distribution within feed. Work has commenced on this.

2. Safety: General toxicity, animal safety, user safety, environmental risk. Work has commenced on this.

3. Efficacy Studies: 3x long-term studies. Efficacy studies to commence in 2027

A priority patent application was made in July 2021 to protect the ruminant feed additive. This is currently undergoing examination at the following patent offices: Australia, Brazil, Canada, China, European Patent Office, Japan, Mexico, New Zealand, United States of America. An additional patent application has been filed at the UK patent office in April 2026 seeking to protect alternative means of reducing enteric methane production and improving animal performance.

GlasPort Rumen Tech intends pursue a strategic partnership with a leading global animal feed company to drive RumenGlas commercial scale-up and growth.

The target partner will be a top-tier global feed company with the commercial reach, regulatory expertise, and distribution network to scale RumenGlas globally. This will also act to enhance credibility with both farmers and regulatory bodies. The partnership would include a joint development and licensing agreement to fund late-stage trials, regulatory submissions and product optimization. Global commercialization of RumenGlas would be through the partner's established channels in key markets (EU, US, LATAM, Asia-Pacific) and would target the methane reduction and feed efficiency segments. Access to these extensive global distribution networks will significantly accelerate the roll out for RumenGlas.

8. PLACING OF NEW ORDINARY SHARES

The New Ordinary Shares to be issued pursuant to the Placing and the Subscription, are to be admitted to trading on AIM, which is expected to take place at 8.00 a.m. on 1 December 2026.

The proceeds of the issue of New Ordinary Shares (after commission and expenses) will be used as outlined above.

The Issue Price of the New Ordinary Shares represents a discount of approximately 56.1 per cent. to the closing mid-market price of 20.5 pence per Existing Ordinary Share on 30 October 2026, being the day the announcement of the proposed Placing and Subscription was made and the last practicable date prior to the Company entering into the Capital Access Window. The New Ordinary Shares will represent approximately 45.2% of the post-issue issued share capital.

The Placing and Subscription are conditional upon, inter alia, the passing of Resolution 1 to be put to Shareholders at the EGM, receipt by Roebuck of the cleared funds from the subscribers for Subscription shares by no later than the day of the EGM, the Placing Agreement becoming unconditional in respect of the Placing Shares and not being terminated in accordance with its terms and Admission occurring by no later than 8.00 a.m. on 1 December 2026.

The Placing Agreement

Pursuant to the terms of the Placing Agreement, Davy, as agent for the Company, conditionally agreed to use their reasonable endeavours to procure subscribers for the Placing Shares. The Placing has not been underwritten.

The Placing Agreement contains customary warranties (in relation to, inter alia, the accuracy of the information in this document and other matters relating to the Company, its subsidiaries, and its business) and indemnities given by the Company to Davy, as well as market standard rights of termination. The Company will pay Davy commissions in respect of those Placing Shares placed by them and subscribed for by Placees who were not existing shareholders.

9. SUBSCRIPTION OF NEW ORDINARY SHARES

Subscription agreements have been agreed with certain subscribers ("**the Subscribers**") under which they agree, subject to the Placing Agreement becoming unconditional, to subscribe for new Ordinary Shares at the Placing Price.

Fuller particulars of the Placing Agreement and subscription agreements are set out in Part II of this document.

10. ADMISSION, SETTLEMENT AND DEALING

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM.

Subject to Resolution 1 being passed, and the other conditions to the Placing and the Subscription being satisfied or waived it is expected that Admission will become effective, and that dealings in the New Ordinary Shares will commence, at 8.00 a.m. on 1 December 2026.

The New Ordinary Shares will, on Admission, rank pari passu in all respects with the Existing Ordinary Shares and will rank in full for all dividends and other distributions declared, made, or paid on Ordinary Shares after Admission.

11. DIVIDEND POLICY

The Directors do not envisage the payment of dividends in the foreseeable future. Any decision in this regard will be announced in due course.

12. EXTRAORDINARY GENERAL MEETING

The Placing and the Subscription are subject to the passing of Resolution 1 set out in the Notice of EGM set out at pages 40 to 44 of this document. The EGM will be held on Monday 30 November 2026 at 9:00 a.m. at the offices of Mason Hayes & Curran LLP, South Bank House, Barrow Street, Dublin D04 TR29, Ireland. The resolutions proposed are as follows.

a. Resolution 1 – to enable the Placing and Subscription

This is a special resolution to enable the issue of the Placing Shares and Subscription Shares by:

- increasing the authorised share capital of the Company;
- authorising the directors to issue the New Ordinary Shares (and, if the Potential Acquisition proceeds, the Potential Acquisition Shares) as "relevant securities" within the meaning of the Companies Act;
- authorising the directors to issue the New Ordinary Shares (and, if the Potential Acquisition proceeds, the Potential Acquisition Shares) as "equity securities" within the meaning of the Companies Act otherwise than pro rata to existing shareholders and otherwise as provided by the Companies Act; and
- approving the participation of directors and management in the Subscription, as described in Part II of this document.

b. Resolutions 2 and 3 – share capital authorisations

These are resolutions authorising the allotment of shares as are routinely proposed at each annual general meeting of the Company, updated to reflect the post-Placing and Subscription share capital and potentially the post-Potential Acquisition share capital.

i. Resolution 2

This is an ordinary resolution to grant a general authority to the directors to allot "relevant securities", which means shares in the Company (other than shares allotted pursuant to an employee share scheme) and rights to subscribe for, or convert any security into, shares.

(i) Paragraph (a) of Resolution 2 authorises the Directors to allot new shares or grant rights to subscribe for or convert securities into Ordinary Shares representing approximately one third of the issued share capital for the time being.

(ii) Paragraph (b) of Resolution 2, in line with guidance issued by the Investment Association, gives the Directors authority to allot new shares or grant rights to subscribe for or convert securities into Ordinary Shares representing approximately two thirds of the total issued share capital immediately following the allotment of the Placing Shares, as reduced by any shares issued under paragraph (i), in connection with a pro rata rights issue to existing shareholders.

ii. Resolution 3

This is a special resolution to authorise the Directors to allot "equity securities" without the application of statutory pre-emption rights in respect of any shares allotted pursuant to:

(i) a rights issue, open offer or other pre-emptive offer, subsect to the limitations of Resolution 2;

(ii) any other kind of offer, for cash up to an aggregate nominal amount of one third of the issued share capital of the Company for the time being;

(iii) any share scheme for employees or directors.

Any allocation to directors of shares or related rights under any scheme for non-executive directors will be subject to the provisions as to flow rate of awards, holding period and clawback as provided in the Executive Long Term Incentive Plan adopted and approved by shareholders on 30 November 2023.

The authorities sought under Resolutions 2 and 3, will expire on the earlier of the 2027 annual general meeting and 30 September 2027.

13. ACTION TO BE TAKEN BY EXISTING SHAREHOLDERS IN RESPECT OF THE EGM.

A Form of Proxy is enclosed for use by Shareholders in connection with the EGM. Whether or not Shareholders intend to be present at the EGM, they are asked to complete the Form of Proxy in accordance with the instructions printed on it so as to be received by the Company's Registrar, Computershare Investor Services (Ireland) Limited, at 3100 Lake Drive, Citywest Business Campus, Dublin 24, D24 AK82, Ireland as soon as possible and in any event no later than 9 a.m. on 28 November 2026. Completion of the Form of Proxy will not preclude a Shareholder from attending and voting at the General Meeting in person should he or she subsequently wish to do so.

14. RECOMMENDATION

At the Extraordinary General Meeting, the Resolution to approve and facilitate the Placing and Subscription set out in the Notice of Extraordinary General Meeting in Part VI of this document will be proposed. The Directors believe that the proposals set out in the resolutions before the meeting are in the best interests of the Company and of shareholders as a whole. Accordingly, the Directors recommend that you vote in favour of the resolutions at the Extraordinary General Meeting, which they intend to do in respect of their own beneficial holding of 2,578,491 Ordinary Shares, representing approximately 2.55 per cent. of the issued share capital.

Yours faithfully,

Tommy Conway

Chairman

PART II - ADDITIONAL INFORMATION

The Fundraising is governed by the following documents

Placing Agreement

- The Placing is governed by a Placing Agreement dated 30 October 2026 made between the Company and Davy ("**the Bookrunner**") in which the Bookrunner has conditionally agreed:

  (i) to use its reasonable endeavours (as agent for the Company) to procure institutional and professional investors as subscribers for the Placing Shares at the Placing Price; and

  (ii) subject to procedures to be determined by the Bookrunner at its sole discretion on a case-by case basis to accept subscribers, other than institutional or professional investors, for the Placing Shares at the Placing Price;

  provided that in the event that subscribers are not obtained for all or any of the Placing Shares there shall be no obligation on the Bookrunner to subscribe for those shares.

- Conditions of the Issue of the Placing Shares

  The obligations of the Bookrunner under the Placing Agreement in respect of the Placing Shares are conditional on, amongst other things:

  (a) the Company having complied with its obligations under the Placing Agreement (to the extent that such obligations fall to be performed prior to Admission);

  (b) the passing of the resolutions to be considered at the EGM;

  (c) the Placing Agreement having become unconditional (save for Admission) and not having been terminated in accordance with its terms prior to Admission;

  (d) Admission having occurred not later than 8.00am on 1 December 2026 or such later date as the Company and the Bookrunner may agree in writing, but in any event not later than 8.00am on the Long Stop Date.

  If

  (i) any of the conditions contained in the Placing Agreement are not fulfilled or waived by the Bookrunner by the respective time or date where specified,

  (ii) any of such conditions becomes incapable of being fulfilled or

  (iii) the Placing Agreement is terminated in the circumstances specified below,

  the Placing will not proceed and the Placee's rights and obligations hereunder in relation to the Placing Shares shall cease and terminate at such time and each Placee agrees that no claim can be made by the Placee in respect thereof. The Bookrunner at its absolute discretion may waive compliance by the Company with the whole or any part of any of the Company's obligations in relation to the conditions in the Placing Agreement or otherwise extend the time for fulfilment of all or any part of such conditions. Any such waiver or extension will not affect Placees' commitments as set out in this Announcement (including this Appendix).

  Neither the Bookrunner, the Company nor any other person shall have any liability to any Placee (or to any other person whether acting on behalf of a Placee or otherwise) in respect of any decision they may make as to whether or not to waive or to extend the time and/or the date for the satisfaction of any condition to the Placing nor for any decision they (or any one of them) may make as to the satisfaction of any condition or in respect of the Placing generally, and by participating in the Placing each Placee agrees that any such decision is within the absolute discretion of the Bookrunner.

- Termination of the Placing Agreement

The Bookrunner is entitled at any time before Admission, to terminate the Placing Agreement in relation to its obligations in respect of the Placing Shares by giving notice to the Company if, amongst other things:

(a) the Company has failed to or is unable to comply with any of its obligations under the Placing Agreement in any material respect; or

(b) any statement in the placing documents has become or been discovered to be untrue, inaccurate or misleading or that there has been a material omission therefrom; or

(c) any warranty given by the Company in the Placing Agreement is, or would be if repeated at any time up to Admission (by reference to the facts then subsisting), untrue, inaccurate or misleading; or

(d) there shall have occurred:

(i) any change, or development involving a prospective change, in national or international, military, diplomatic, monetary, economic, political, financial, industrial or market conditions or exchange rates or exchange controls, or any incident of terrorism or outbreak or escalation of hostilities or any declaration by the UK, the Republic of Ireland or the US of a national emergency or war or any other calamity or crisis; or

(ii) a suspension of trading in securities generally on the London Stock Exchange, or New York Stock Exchange or trading is limited, or minimum prices established on any such exchange; or

(iii) a declaration of a banking moratorium in London, Dublin or by the US federal or New York State authorities or any material disruption to commercial banking or securities settlement or clearance services in the US, the Republic of Ireland or the UK,

(iv) in the opinion of Davy, acting in good faith, a material adverse change or any development reasonably likely to involve a prospective material adverse change, in the condition (financial, operational, legal or otherwise) or the earnings, business affairs or business prospects of the Company or its group which is material in the context of its group as a whole taken as a whole, whether or not arising in the ordinary course of business and whether or not foreseeable at the date of the Placing Agreement, since the date of the Placing Agreement (provided that a further depletion in the working capital available to the Company's group following the date of the Placing Agreement (unless such depletion would lead to its group not having adequate working capital to finance its operations, after taking account of the proceeds of the Placing) will not constitute a material adverse change or prospective material adverse change)

which, in each case, in the opinion of the Bookrunner acting in good faith, would or would be likely to prejudice materially the Company or the Placing, or make the success of the Placing doubtful or makes it impracticable or inadvisable to proceed with the Placing.

Upon such termination, the parties to the Placing Agreement shall be released and discharged (except for any liability arising before or in relation to such termination) from their respective obligations under or pursuant to the Placing Agreement, subject to certain exceptions.

By participating in the Placing, Placees agree that the exercise by the Bookrunner of any right of termination or other discretion under the Placing Agreement shall be within the absolute discretion of the Bookrunner and that the Bookrunner need not make any reference to Placees in relation thereto and that the Bookrunner shall have no liability to Placees whatsoever in connection with any such exercise or failure so to exercise.

- Restrictions on issues of shares and other securities by the Company

  The Company has undertaken to the Bookrunner under the Placing Agreement that, during the period commencing on the date of the Placing Agreement until 90 days after the date of Admission, it will not without the prior consent of the Bookrunner allot or issue, or enter into any agreement or arrangement which would give rise to an obligation or an increased obligation (in each case whether contingent or otherwise) to allot or issue, any share or any instrument or security convertible into a share in the capital of the Company (save for the allotment and issue of Ordinary Shares pursuant to the Placing), provided that the Bookrunner will not unreasonably withhold its consent to an allotment or allotments of Ordinary Shares to be issued in consideration for the transfer by the allottees to the Company of their shares in GlasPort Bio Limited or GlasPort Rumen Tech Limited

- Warranties and indemnities

  The Placing Agreement contains warranties by the Company in relation to information in this document and announcements, adequacy of working capital, the 2025 financial statements, the 2026 interim accounts for the six months ended 30 June 2026, the Group's financial trading and financial position, commercial matters, verification of this document, taxation, solvency, share capital, intellectual property, authority to carry on business, information on the public record, corporate capacity, Company records and public filings, compliance with laws, including environmental and US securities laws.

  The Placing Agreement contains indemnities in favour of the Bookrunner in respect of certain matters including breach of law, misrepresentation, breach of warranty and generally in favour of the Bookrunner. The Bookrunner has the right to terminate the Placing Agreement in a number of contingencies including breach of warranty and material adverse change.

It was announced on 5 November 2026 that commitments to subscribe for 62,291,018 Placing Shares had been received by the Bookrunner.

Subscriptions

The Subscription is governed by separate subscription agreements between the respective subscribers and the Company, whereby the Subscribers agree to subscribe for new Ordinary Shares at the Placing Price. It was announced on 5 November 2026 that agreements to subscribe for 21,022,999 Subscription Shares had been agreed.

PART III RISK FACTORS

Potential investors and Shareholders should carefully consider the risks described below before making a decision to invest in the Company. This Part contains what the Directors believe to be the principal risk factors associated with an investment in the Company.

This list is not exhaustive and that other risk factors will apply to an investment in the Company. If any of the following risks actually occur, the Company's business, financial condition and/or results or future operations could be materially adversely affected. In such circumstances, the trading price of the New Ordinary Shares could decline, and an investor may lose all or part of their investment.

There can be no certainty that the Company will be able to implement successfully the strategy set out in this document. Additional risks and uncertainties not currently known to the Directors or which the Directors currently deem immaterial may also have an adverse effect on the Company.

This document contains forward-looking statements that involve risks and uncertainties. The Company's actual results could differ materially from those anticipated in the forward-looking statements as a result of many factors, including the risks faced by the Company which are described below and elsewhere in this document. Prospective investors should carefully consider the other information in this document. The risks listed below do not necessarily comprise all the risks associated with an investment in the Company.

An investment in the Company may not be suitable for all recipients of this document. Investors are accordingly advised to consult an independent financial adviser authorised or exempt under the Investment Intermediaries Act 1995 of Ireland or an authorised investment firm within the meaning of the European Communities (Markets in Financial Instruments) Regulations 2007 and in the case of UK resident shareholders, an independent financial adviser who is authorised to carry on a regulated activity under the Financial Services and Markets Act 2000 of the UK) who specialises in advising upon the acquisition of shares and other securities before making a decision to invest.

1. Principal risks and uncertainties relating to the Group and its business

Business Strategy May Change

The future success of the Group will depend on the Directors' ability to continue to effectively implement its business strategy. In particular, the pursuit of that strategy may be affected by changes in social, political, or economic factors related to energy and the environment, or by changes in the competitive environment in the markets in which the Group currently operates or expects to operate. If such changes were to materialise the Directors may decide to change certain aspects of the Group's strategy. This might entail the development of alternative products and services, which would place additional strain on the Group's capital resources and may adversely impact on the revenues and profitability of the Group.

Dependence on Key Executives and Personnel

The Group's future success is substantially dependent on the continued services and performance of its executive Directors and senior management and its ability to attract and retain suitably skilled and experienced personnel. The Directors cannot give assurances that members of the senior management team and the executive Directors will continue to remain within the Group.

The loss of the services of any of the Directors, members of senior management or other key employees could have a material adverse effect upon the Group's business and results of operations. Finding and hiring any such replacements could be costly and might require the Company to grant significant equity awards or other incentive compensation, which could adversely impact its financial results.

Cash flow and fair value interest rate risk

As the Group has no significant interest-bearing assets, the Group's income and operating cash flows are substantially independent of changes to market interest rates. Borrowings issued at variable rates expose the Group to cash flow interest rate risk.

Management of Growth

The ability of the Group to implement its strategy requires effective planning and management control systems. The Group's growth plans may place a significant strain on its management and operational, financial, personnel and facilities resource. Therefore, the Group's future growth and prospects will depend on its ability to manage this growth. The Group's objectives may not be fulfilled. There can be no guarantee that the Company will achieve the level of success that the Board expects.

Trading Risks

There is a risk that if all or a significant part of the Group's business underperforms, the proposed investment programme may need to be reduced or curtailed accordingly, despite the funding from the Placing. There are risks as well as opportunities across all the sectors in which the Group operates.

Economic, Political, Judicial, Administrative, Taxation or other Regulatory Factors

The Group may be adversely affected by changes in economic, political, judicial, administrative, taxation or other regulatory factors, in the areas in which the Group operates and conducts its principal activities. In particular, failure to achieve EPA approval would have a significant negative impact on the Group's future performance. These activities take place in many locations internationally and the Group maintains active awareness of conditions to enable contingency planning.

Taxation Risk

Any change in the Company's tax status or in tax legislation or its interpretation could affect the Company's ability to provide returns to Shareholders and/or alter the post-tax returns to Shareholders. Statements in this document concerning the taxation of the Company and its investors are based upon current tax law and practice which is subject to change.

Liquidity Risk

The Group seeks to manage financial risk by ensuring that sufficient liquidity is available to meet foreseeable needs and by investing cash assets safely and profitably.

Foreign Currency Risk

The Group's main operating assets are based in the EU and the United Kingdom and the majority of its costs are denominated in Euro and in pounds sterling. The Group has exposure to foreign exchange risk in respect of its product sourcing and procurement business. It mitigates this risk by mainly purchasing euros and sterling at a fixed rate forward and using this rate in establishing a selling price for its goods in order to both maintain an acceptable margin and to ensure the Group has sufficient balances of the appropriate currencies. The Group reports its financial statements in pounds sterling.

Accounting Standards Risk

Changes in accounting standards may impact on the Group's financial position

2. Risks relating to the Ordinary Shares

The Market Price of the Ordinary Shares may Fluctuate Significantly

The market price of the Ordinary Shares may, in addition to being affected by the Company's actual or forecast operating results, fluctuate significantly as a result of factors beyond the Company's control, including among others:

(a) changes in securities analysts' recommendations or the failure to meet the expectations of securities analysts;

(b) changes in the performance of the food industry as a whole and of the Group's competitors;

(c) fluctuations in stock market prices and volumes, and general market volatility; and

(d) the introduction of new legislation affecting the food industry.

Any or all of these events could result in a material decline in the market price of the Ordinary Shares, regardless of the actual performance of the Group. Shareholders should be aware that the value of the Ordinary Shares may go down as well as up and may not reflect the underlying asset values or prospects of the Company. Investors may therefore realise less than, or lose all of, their investment.

Future Need for Access to Capital

The Group may need to raise further funds to carry out the implementation of its business plan. Any additional equity financing may be dilutive to Shareholders, and debt financing, if available, may involve restrictions in financing and operating activities. In addition, there can be no assurance that the Group will be able to raise additional funds when needed or that such funds will be available on terms favourable to it. If the Group is unable to obtain additional financing as needed it may be required to reduce the scope of its operations or anticipated expansion or cease trading.

Investment in Public Quoted Securities

Investment in securities traded on AIM is perceived to involve a higher degree of risk and be less liquid than investment in companies whose securities are listed on the ‘‘Official List’’ in the UK and traded on the London Stock Exchange’s main market for listed securities. An investment in Ordinary Shares traded on AIM may be difficult to realise. AIM has been in existence since 1995 and is a market designed for small and growing companies but its future success and liquidity as a market for Ordinary Shares cannot be guaranteed.

Potentially Volatile Share Price and Liquidity

The share price of companies quoted on AIM can be highly volatile and shareholdings illiquid. The price at which the Ordinary Shares are quoted and the price at which investors may realise their investment in the Company may be influenced by a significant number of factors, some specific to the Company and its operations and some which affect quoted companies generally.

These factors could include the performance of the Company, large purchases or sales of Ordinary Shares, legislative changes and general economic, political, or regulatory conditions.

3. Risks relating to the GlasPort Bio and GlasPort Rumen Tech businesses, the Potential Acquisition, and the Fundraising

Intellectual Property and Competition Risk

GlasPort Bio operates in the competitive field of greenhouse gas mitigation in agriculture, there is a risk of potential infringement claims from competitors or other patent holders, which may result in costly litigation or restrictions on product commercialization. The effectiveness of GlasPort Bio's proprietary technologies, namely GasAbate and RumenGlas, may depend on the company's ability to maintain trade secrets.

Product Risk

The improper delivery of GasAbate and RumenGlas products may adversely impact the Group’s reputation. Key markets into which the products are sold may not sustain or grow at the same pace they have historically or as fast as the forecasts might indicate. GlasPort Bio and Rumen Tech’s supply chains may be affected by pricing risk, reducing the profitability of the products. These products are exposed to regulatory and policy risk in the event of changes thereto in Ireland, the EU and elsewhere.

The anticipated revenue, operating efficiencies and other benefits may fail to materialise or be materially lower than have been estimated.

There is a risk that the Group may encounter technical, engineering, regulatory or commercial challenges in developing and deploying a dosage system that operates safely, reliably and cost-effectively at scale across differing farm types, operating conditions, local regulatory requirements and slurry storage systems, which

could delay deployment, increase installation or operating costs and adversely affect customer adoption and the commercialisation of the Group's technology.

The Roebuck Board believes that there is a strong strategic and financial rationale for the Fundraising. However, the expected benefits that form a significant part of the rationale for this may not develop, for various reasons, including because the assumptions upon which the Roebuck Board made its decisions may prove to be incorrect. Under any of these circumstances, the benefits anticipated by the Roebuck Board may not be achieved as expected, or at all, or may be delayed, or may involve additional costs. To the extent that this occurs, the price of Roebuck shares may suffer.

Increased influence of certain major shareholders

Whilst none of Roebuck's major shareholders have or will have different voting rights attached to the Roebuck shares they hold in the Company, as a result of the Fundraising, the shareholding size and the influence they may be able to exert in respect of the Group may increase and may have the ability to cause or take actions that are not in, or may conflict with, the best interests of the Company or Shareholders as a whole.

If the Fundraising does not proceed, there will be wasted costs and a potential adverse impact on Roebuck's reputation

If the Fundraising is not approved, Roebuck and its management team will have spent time and cost in connection with it , which could otherwise have been spent more productively in connection with the other activities of the Group. There may also be an adverse impact on the reputation of the Group as a result of media scrutiny arising in connection with an unsuccessful fundraising. In the future, this may make it more difficult for Roebuck to raise money from investors.

PART IV - FINANCIAL INFORMATION

Roebuck Food Group Consolidated Balance Sheet as at 30 June 2026

Roebuck Food Group plc
Financial position
As at 30 June 2026

	As at 30 June 2026 (Unaudited)	As at 30 June 2025 (Restated)	As at 31 December 2025 (Audited)
	£'000	£'000	£'000
ASSETS			
Non-current assets			
Goodwill	966	966	966
Investments – fair value	833	833	833
Equity option derivative – fair value	928	928	928
Intangible assets	5,067	5,502	5,281
Property, plant and equipment	1,126	1,191	1,120
	8,920	**9,420**	**9,128**
Current assets			
Trade and other receivables	1,773	1,847	1,996
Inventories	1,021	1,377	1,494
Cash and cash equivalents	1,162	2,848	1,759
	3,956	**6,072**	**5,249**
TOTAL ASSETS	**12,876**	**15,492**	**14,377**
Equity attributable to equity holders of the parent And non-controlling interest			
Share capital	2,077	2,077	2,077
Share premium account	8,938	8,938	8,938
Other reserves	(6)	(99)	(54)
Retained earnings	(4,826)	(2,403)	(4,005)
Equity attributable to owners of the parent	**6,183**	**8,513**	**6,956**
Non-controlling interest	**3,104**	**4,279**	**3,665**
TOTAL EQUITY	**9,287**	**12,792**	**10,621**
Non-current liabilities			
Borrowings	9	17	13
Deferred tax	607	74	607
	616	**91**	**620**
Current liabilities			
Trade and other payables	1,330	2,322	2,354
Borrowings	1,643	287	782
	2,973	**2,609**	**3,136**
TOTAL EQUITY AND LIABILITIES	**12,876**	**15,492**	**14,377**

The above does not constitute the statutory financial statements of the Company. Financial statements for year ended 31 December 2025 have been signed, audited with an unqualified opinion, and delivered for filing to the Registrar of Companies in Ireland..

Financial information on GlasPort Bio

P&L €'000	FY 2023	FY 2024	FY 2025* *18m*	H1 2026
Revenue	-	32	208	293
Cost of Sales	-	(43)	(403)	(302)
Gross loss	-	(11)	(195)	(9)
(Loss)/Profit on continuing activities before Taxation	(327)	(437)	(2,037)	(812)
Tax	-	-	47	-
Total comprehensive (expense)/income	**(327)**	**(437)**	**(1,990)**	**(812)**

Assets €'000	**FY 2023**	**FY 2024**	**FY 2025**	**H1 2026**
Intangible assets	322	478	431	452
Property, plant, and equipment	134	114	100	182
Trade and other receivables	9	7	350	235
Cash and cash equivalents	215	184	1,755	833
Total assets	**679**	**782**	**2,636**	**1,702**

Equity & Liabilities €'000	**FY 2023**	**FY 2024**	**FY 2025**	**H1 2026**
Share Capital	4*	4*	6*	6*
Share premium account	600	1,100	5,018	5,029
Retained (Deficit)/earnings	(302)	(740)	(2,729)	(3,586)
Non-Current Liabilities - trade and other payables	(180)	-	-	-
Current Liabilities - trade and other payables	(201)	(421)	(348)	(259)
Total Liabilities	**(381)**	**(421)**	**(348)**	**(259)**
Total Equity and Liabilities	**679**	**782**	**2,636**	**1,702**

Source: Management Accounts
Notes: Financials reflect GlasPort Bio only, not including GlasPort Rumen Tech.
FY 2023 & FY 2024 reflect the twelve months ending 30 June in those years.
FY 2025 reflects the period ending 31 December.2025
H1 2026 reflects the six months ending 30 June 2026
The above does not constitute the statutory financial statements of GlasPort Bio. Financial statements for year ended 31 December 2025 have been signed, audited with an unqualified opinion, and delivered for filing to the Registrar of Companies in Ireland.

PART V

DEFINITIONS

The following words and expressions shall have the following meanings in this document unless the context otherwise requires:

"€'000"	thousand Euros;
"£'000"	thousand pounds sterling;
"AD"	anaerobic digestion;
"ADG"	average daily gain;
"AIM Rules"	the AIM Rules for Companies published by the London Stock Exchange governing admission to, and the operation of, AIM as in force as at the date of this document or, where the context so required, as amended or modified after the date of this document;
"Admission"	admission of the New Ordinary Shares to the AIM market of the London Stock Exchange;
"AIM"	the AIM Market operated by the London Stock Exchange;
"the Bookrunner"	J & E Davy Unlimited Company;
"c."	circa (approximately);
"Capital Access Window"	the suspension of trading in the Company's shares on AIM from 7:30 am 2 November 2026 to 7:30 am on 6 November 2026;
"CEO"	Chief Executive Officer;
"CFCF"	Carbon Farming Removal Framework of the EU;
"CH_4"	methane;
"CO_2"	carbon dioxide;
"CRO"	Chief Research Officer;
"CSO"	Chief Scientific Officer;
"Companies Act"	the Companies Act 2014 of Ireland;
"Company"	Roebuck Food Group plc
"Davy"	J&E Davy Unlimited Company, trading as Davy;
"Directors" or "Board"	the directors of the Company as at the date of this document, being Tommy Conway, Justin McCarthy, Aidan Hughes, and Seán Savage;
"EBITDA"	earnings before interest, tax, depreciation and amortization;
"EPA"	Environmental Protection Agency of Ireland;
"EPO"	European Patent Office;
"EU"	European Union;
"Euroclear"	Euroclear Bank SA/NV, the central securities depository;
"Existing Group"	Roebuck Food Group plc and its subsidiaries at the date of this document;
"Existing Ordinary Shares"	the 101,143,944 Ordinary Shares in issue as of the date of this document;
"Extraordinary General Meeting" or "EGM"	the extraordinary general meeting of the Company to consider the Resolutions, notice of which is set out in Part VI of this document;
"FCE"	feed conversion efficiency;
"Form of Proxy" or "Proxy Form"	the form of proxy enclosed with this document for use by Shareholders in connection with the Extraordinary General Meeting;

"Foro"	Foro Food Solutions Limited, a wholly-owned subsidiary of the Company and a company incorporated and registered in Ireland under company number 544977 whose registered office is at 6th Floor South Bank House, Barrow Street, Dublin D04 TR29, Ireland;
"FSMA"	the UK Financial Services and Markets Act 2000 (as amended);
"Fundraising"	the raising of approximately €9 million through the Placing and Subscription;
"FY"	financial year of 12 months;
"GHG"	greenhouse gases;
"GlasPort Companies"	GlasPort Bio and GlasPort Rumen Tech;
"GlasPort Bio"	GlasPort Bio Limited;
"GlasPort Rumen Tech"	GlasPort Rumen Tech Limited;
"Group"	the Company and its subsidiaries as at the date of this document;
"HFC"	hydrofluorocarbons;
"HY", "H1:	half year of 6 months, first half year in a calendar year;
"IP"	intellectual property;
"Ireland" or the "Republic of Ireland"	the island of Ireland excluding Northern Ireland, and the word "**Irish**" shall be construed accordingly;
"Irish IMC Rules"	the Central Bank (Investment Market Conduct) Rules 2019 of Ireland;
"Issue Price"	9 pence, being the issue price per Placing Share and Subscription Share;
"KPI"	key performance indicator;
"kt"	kilotons;
"LATAM"	Latin America;
"Legacy Businesses"	Foro Food Solutions Limited and Moorhead & McGavin Limited, wholly-owned subsidiaries of the Company;
"Loan"	the initial €1 million loan to be provided by the Company to GlasPort Bio following completion of the Fundraising and prior to the Potential Acquisition;
"Long Stop Date"	31 December 2026;
"London Stock Exchange"	London Stock Exchange plc;
"M&M"	Moorhead & McGavin Limited, a wholly-owned subsidiary of Roebuck and a company incorporated and registered in the UK under company number SC012722 whose registered office is at 21 Newhut Road, Braidhurst Industrial Estate, Motherwell ML1 3ST, Scotland;
"MRV"	the measurement/monitoring, reporting, and verification system, a structured framework used to track, calculate, document, and independently validate GHG emissions, climate actions, or carbon removals;
"New Ordinary Share"	an Ordinary Share to be issued pursuant to the Placing or the Subscription;
"NH_3"	ammonia;
"NIL"	national inventory list;
"Notice"	the notice of the EGM as set out in Part VII of this document;
"Official List"	the official list of the UKLA;

"Original Shareholders"	Killian O'Briain, Ruairi Friel, and Vincent O'Flaherty, and certain shareholders of GlasPort Bio and GlasPort Rumen Tech;
"Ordinary Shares"	ordinary shares of €0.025 in the capital of the Company;
"P&L"	profit and loss account;
"Placees"	(a) persons procured by the Bookrunner to subscribe for Placing Shares pursuant to the provisions of the Placing Agreement; and (b) persons who approached the Company or the Bookrunner requesting an allocation of Placing Shares who, subject to the approval of and in accordance with procedures determined by the Bookrunner in its absolute discretion, were accepted by the Company as subscribers for Placing Shares and for avoidance of doubt, excluding the Subscribers;
"Placing Agreement"	he placing agreement dated 30 October 2026 between (1) the Company and (2) Davy;
"Placing Shares"	the 62,291,018 New Ordinary Shares that are to be allotted and issued pursuant to the Placing;
"Potential Acquisition"	the potential acquisition by the Company of shares (other than management growth shares) in GlasPort Bio and/or in GlasPort Rumen Tech not owned by the Company;
"Potential Acquisition Shares"	Ordinary Shares issued as consideration for the Potential Acquisition;
"R&D"	research and development;
"Resolutions"	the Resolutions set out in the Notice;
"Restricted Jurisdiction"	each and any of Australia, Canada (and its territories and possessions), Japan, the Republic of South Africa, the USA, and any other jurisdiction where the extension or availability of the Shares would breach any applicable law
"RNS"	Regulatory News Service;
"Roebuck"	Roebuck Food Group plc;
"Shareholder"	a registered holder of Ordinary Shares from time to time;
"Subscription Shares"	the 21,022,999 New Ordinary Shares that are to be allotted and issued pursuant to subscription agreements;
"TAM"	total addressable market;
"UK" or "United Kingdom"	the United Kingdom of Great Britain and Northern Ireland;
"UK POATRs"	the UK Public Offers and Admissions to Trading Regulations 2024;
"United Kingdom Listing Authority" or "UKLA"	the UK Listing Authority, being the Financial Conduct Authority acting in its capacity as the competent authority for the purposes of FSMA; and
"US", "USA" or "United States"	the United States of America, each State thereof (including the District of Columbia), its territories, possessions and all areas subject to its jurisdiction.
"USPTO"	United States Patent and Trademark Office.

PART VI

NOTICE OF EXTRAORDINARY GENERAL MEETING

of

ROEBUCK FOOD GROUP PUBLIC LIMITED COMPANY

(Registered in Ireland under the Companies Act 2014 of Ireland, No 51842)

NOTICE is hereby given that an Extraordinary General Meeting of Roebuck Food Group plc will be held at South Bank House, Barrow Street, Dublin D04 TR29, Ireland at 9 **a.m. on Monday 30 November 2026 to consider and, if thought fit, pass the following ordinary and special resolutions:**

1. Special Resolution to enable the Placing and Subscription (and, if required, the allotment of Potential Acquisition Shares)

As a special resolution, that:

(a) the authorised share capital of the company be increased from €5,000,000 divided into 200,000,000 shares of €0.025 each to €20,000,000 divided into 800,000,000 shares of €0.025 each by the addition of €15,000,000 divided into 600,000,000 shares of €0.025 each, all such shares ranking pari passu, and that:

(i) Clause 4 of the memorandum of association be altered so as to read:

"The share capital of the company is €20,000,000 divided into 800,000,000 shares of €0.025 each, or, if so fixed, such amount as may from time to time be fixed by ordinary resolution pursuant to section 83 of the Companies Act 2014 or by special resolution."; and

(ii) Article 2 of the articles of association be amended so as to read:

"The share capital of the Company is as stated in the memorandum of association.";

(b) the Directors be and are hereby generally and unconditionally authorised for the purposes of section 1021 of the Companies Act 2014 (the "**Companies Act**") and Article 6 of the Articles of Association and in substitution for any existing authorities to exercise all the powers of the Company to allot an amount of relevant securities (as defined by that section) equal to:

(i) the aggregate amount of Placing Shares and Subscription Shares;

(ii) such amount of shares (not to exceed, as at the time of allotment, the authorised but unissued share capital of the Company) as are required to be allotted and issued for the purposes of the Potential Acquisition;

such authorisation to expire on the earlier of (A) the conclusion of the Company's annual general meeting in 2027 and (B) 30 September 2027; and

(c) the Directors be and are hereby empowered pursuant to section 1023(3) of the Companies Act to allot equity securities (as defined in section 1023(1) of the Companies Act) of the Company for cash pursuant to the authority to be conferred by sub-paragraph (b) of this resolution, as if section 1022 of the Companies Act did not apply to any such allotment, provided that this power shall be limited to the allotment of the Placing Shares and the Subscription Shares (and, if required, the Potential Acquisition Shares), being equity securities as defined by that section, such power to expire on the earlier of the (A) the conclusion of the Company's annual general meeting in 2027 and (B) 30 September 2027.

2. Ordinary Resolution to update Directors' authorisation to allot relevant securities

As an ordinary resolution, in substitution for and replacing any such existing authorities (other than the authority in Resolution 1(b)), that the Directors of the Company be and are hereby generally and

unconditionally authorised for the purposes of section 1021 of the Companies Act and Article 6 of the Articles of Association to exercise all the powers of the Company to allot relevant securities (as defined by that section) and shares pursuant to employees' share schemes:

(a) in the case of relevant securities comprising equity securities (as defined in section 1023(1) of the Companies Act:

(i) until the completion of the Potential Acquisition, up to a maximum aggregate nominal amount equivalent to one-third of the nominal amount of the issued share capital immediately following the allotment of the Placing Shares and Subscription Shares; and

(ii) following the completion of the Potential Acquisition, up to a maximum aggregate nominal amount equivalent to one-third of the nominal amount of the issued share capital immediately following the allotment of Potential Acquisition Shares;

(b) in the case of relevant securities, comprising equity securities (as defined in section 1023(1) of the Companies Act):

(i) until the completion of the Potential Acquisition, up to a maximum aggregate nominal amount equivalent to two-thirds of the nominal amount of the issued share capital immediately following the allotment of the Placing Shares and Subscription Shares (including within such limit any shares and rights to subscribe for or convert any security into shares allotted under subparagraph (a)(i) of this resolution); and

(ii) following the completion of the Potential Acquisition, up to a maximum aggregate nominal amount equivalent to two-thirds of the nominal amount of the issued share capital immediately following the allotment of Potential Acquisition Shares(including within such limit any shares and rights to subscribe for or convert any security into shares allotted under subparagraphs (a)(i) and (a)(ii) of this resolution);

in either case of (b)(i) or (ii) in connection with or pursuant to an offer or invitation by way of a rights issue or open offer in favour of holders of Ordinary Shares in proportion (as nearly as practicable) to the respective number of Ordinary Shares held by them on the record date for such allotment (and holders of any other class of equity securities entitled to participate therein or, if the Directors consider it necessary, as permitted by the rights of those securities), but subject to such exclusions or other arrangements as the Directors may consider necessary or appropriate to deal with fractional entitlements, treasury shares, record dates or legal, regulatory or practical difficulties which may arise under the laws of, or the requirements of, any regulatory body or stock exchange in any territory;

provided that this authority shall expire on the earlier of (A) the conclusion of the Company's annual general meeting in 2027 and (B) 30 September 2027, save that the Company may before such expiry make offers or agreements which would or might require relevant securities to be allotted after such expiry and the Directors may allot relevant securities pursuant to such offer or agreement as if the authority conferred hereby had not expired.

3. Special Resolution to update Directors' power to allot equity securities

As a special resolution, subject to the passing of Resolution 2, and in addition to the authority in Resolution 1(c) that the Directors be and are hereby empowered pursuant to section 1023(3) of the Companies Act to allot equity securities (as defined in section 1023(1) of the Companies Act) of the Company, to include the re-issue of treasury shares, for cash under the authority given by that resolution as if section 1022 of the Companies Act did not apply to any such allotment or re-issue provided that this power shall be limited to the allotment of equity securities and the re-issue of treasury shares (as applicable) for cash:

(a) in connection with or pursuant to an offer or invitation (but in the case of the authority granted under Resolution 2(b), by way of a rights issue or open offer only) in favour of holders of Ordinary Shares in proportion (as nearly as practicable) to the respective number of Ordinary Shares held by them on the record date for such allotment or sale (and holders of any other class of equity securities entitled to participate therein or if the Directors consider it necessary,

as permitted by the rights of those securities) but subject to such exclusions or other arrangements as the Directors may deem necessary or appropriate to deal with fractional entitlements, treasury shares, record dates, or legal, regulatory or practical problems which may arise under the laws of, or the requirements of, any regulatory body or stock exchange in any territory or otherwise howsoever;

(b) in the case of the authority granted under Resolution 2(a)(i), and otherwise than pursuant to sub-paragraph (a) of this resolution, up to an aggregate nominal amount equivalent to one third of the nominal amount of the Company's issued ordinary share capital (excluding treasury shares) immediately following the allotment and issue of the Placing Shares and Subscription Shares;

(c) in the case of the authority granted under Resolution 2(a)(ii), and otherwise than pursuant to sub-paragraphs (a) or (b) of this resolution, up to an aggregate nominal amount equivalent to one third of the nominal amount of the Company's issued ordinary share capital (excluding treasury shares) immediately following the allotment and issue of the Potential Acquisition Shares;

(d) in connection with share schemes for employees or directors.

provided that this power shall expire on the earlier of the (A) the conclusion of the Company's annual general meeting in 2027 and (B) 30 September 2027, except that the Company may before such expiry make offers or agreements which would or might require equity securities to be allotted, or treasury shares to be sold, after such expiry and notwithstanding such expiry the Directors may allot equity securities, or sell treasury shares, in pursuance of such offers or agreements as if the power conferred hereby had not expired.

By Order of the Board.

Aidan Hughes
Secretary
Roebuck Food Group plc

Dated 6 November 2026

Registered Office

6th Floor
South Bank House
Dublin 4
D04 TR29
Ireland

NOTES TO THE NOTICE OF EGM

Record date

1 The Company, pursuant to Section 1087G of the Companies Act 2014, has specified that only those shareholders registered in the Register of Members of the Company as (i) at the close of business on the day four days prior to the EGM; or (ii) if the EGM is adjourned, at the close of business on the day four days prior to the adjourned EGM, shall be entitled to participate and vote at the EGM. Changes in the register after this time will be disregarded in determining the right of any person to attend, speak, ask questions and/or vote at the meeting.

Appointment of proxies and exercise of voting rights

2 Following the migration of the Company's ordinary shares from the CREST system ("**CREST**") to the system operated by Euroclear Bank SA/NV ("**Euroclear Bank**") on 15 March 2022, the process for appointing a proxy and/or voting at the meeting will now depend on the manner in which you hold your Ordinary Shares in the Company (see paragraph 3 below).

3 The ways in which a holder of Ordinary Shares can exercise a right to vote will depend on the manner in which such shares are held:

(a) in the case of shareholders who are registered as members and at present hold Ordinary Shares in certificated (i.e. paper) form:

(i) by attending the EGM in person; or

(ii) by appointing the Chair of the EGM or another person as a proxy to attend the EGM and vote on your behalf by returning a completed Form of Proxy in accordance with paragraph 4; or

(b) in the case of holders of CREST Depository Interests ("**CDIs**") ("**CDI Holders**"):

(i) by sending electronic voting instructions to Euroclear Bank via Broadridge Financial Solutions Limited ("**Broadridge**"), a third-party service provider; or

(ii) by appointing a proxy via the Broadridge Global Proxy Voting Service to attend and vote at the meeting; and

(c) in the case of persons who hold their interests in Ordinary Shares through a participant account in the Euroclear Bank SA/NV ("**Euroclear Bank**") system (the "**EB System**") ("**EB Participants**"):

(i) by sending electronic voting instructions to Euroclear Bank via SWIFT or to EasyWay Corporate Actions; or

(ii) by sending a proxy voting instruction to Euroclear Bank to appoint a third party (other than Euroclear Nominees Limited (i.e. the nominee of Euroclear Bank) ("**Euroclear Nominees**") or the Chair of the EGM) to attend and vote at the meeting.

Persons who hold their interests in the Ordinary Shares as Belgian law rights through the EB System or as CDIs should consult with their stockbroker or other intermediary at the earliest opportunity for further information on the processes and timelines for submitting proxies and voting instructions for the EGM through the respective systems.

For voting services offered by custodians holding Irish corporate securities directly with Euroclear Bank, please contact the relevant custodian.

Appointment of proxies by registered members

4 A Form of Proxy is enclosed. Shareholders who are registered as members who wish to appoint a proxy should complete the Form of Proxy in accordance with the instructions printed thereon and return it to the Company's Registrar, Computershare Investor Services (Ireland) Limited, at 3100 Lake Drive, Citywest Business Campus, Dublin 24, D24 AK82, Ireland as soon as possible but in any event so as to be received by the Company's Registrar no later than 9 a.m. on Saturday 28 November 2026.

5 The completion and return of a Form of Proxy will not preclude a shareholder from attending and voting in person at the EGM, or any adjournment thereof, should they wish to do so.

Proxy voting by CDI Holders

6 Euroclear UK & Ireland Limited ("**EUI**"), the operator of the CREST, has arranged for holders of CDIs to issue voting instructions relating to Ordinary Shares via a third-party service provider, Broadridge. CDI Holders can complete and submit electronic voting instructions or proxy appointment instructions electronically through Broadridge.

7 If you hold CDIs and wish to submit electronic voting instructions or proxy appointment instructions you must use the Broadridge Global Proxy Voting service. To avail of the voting service, you will need to complete the Meetings and Voting Client Set-up Form (CRT408) prescribed by Broadridge. Completed application forms should be returned to EUI (signed by an authorised signatory with another relevant authorised signatory copied for verification purposes) to the following email address: eui.srd2@euroclear.com. Fully completed application forms will be shared by EUI with Broadridge. This will enable Broadridge to contact you and share further detailed information on the service offering and initiate the process for granting your access to the Broadridge platform.

8 Broadridge will set a voting deadline by which time electronic voting instructions or proxy appointment instructions must be received by it for use at the EGM. Broadridge's voting deadline will be earlier than Euroclear Bank's voting instruction deadline. Voting instructions cannot be changed or cancelled after Broadridge's voting deadline.

9 CDI Holders are strongly encouraged to familiarise themselves with the arrangements with Broadridge, including the voting deadlines and procedures and to take, as soon as possible, any further actions required by Broadridge in order that they may avail of this voting service.

Proxy voting by EB Participants

10 EB Participants can submit proxy appointments (including voting instructions) electronically in the manner described in the document issued by Euroclear Bank in February 2022 and entitled "Euroclear Bank as issuer CSD for Irish corporate securities" (the "**EB Services Descrip\tion**"), which is available on the Euroclear Bank website (www.euroclear.com).

EB Participants can either send:

(a) electronic voting instructions to instruct Euroclear Nominees to either itself, or by appointing the Chair of the EGM as a proxy:

(i) vote in favour of all or a specific resolution(s);

(ii) vote against all or a specific resolution(s);

(iii) abstain in respect of all or a specific resolution(s); or

(iv) give a discretionary vote to the Chair of the EGM for all or a specific resolution(s); or

(b) a proxy voting instruction to appoint a third party (other than Euroclear Nominees or the Chair of the EGM), who may be a corporate representative or the EB Participant themselves, to attend the meeting and vote the number of Ordinary Shares specified in the proxy voting instruction by providing Euroclear Bank with the proxy details as requested in its notification (e.g. proxy first name, proxy last name, proxy address). There is no facility to offer a letter of representation or to appoint a corporate representative other than through submission of third-party proxy appointment instructions.

11 Euroclear Bank will, wherever practical, aim to have a voting instruction deadline of one hour prior to the Company's proxy appointment deadline (being 48 hours before the time appointed for the EGM or any adjournment of the EGM). Voting instructions cannot be changed or cancelled after Euroclear Bank's voting deadline. EB Participants are strongly encouraged to familiarise themselves with the arrangements with Euroclear Bank, including the voting deadlines and procedures.

12 Capitalised terms used but not otherwise defined in this Notice shall have the meanings given to such terms in the Circular dated 6 November 2026 of which this Notice forms part.

END